Sonnest, Inc. is pre-clinical healthcare company developing Electrast™, an ultrasound imaging drug that circulates through the body in the inactive state (dark on ultrasound) and is selectively activated (turned on) in the myocardium. With Electrast™ doctors will be able to evaluate perfusion of the heart quickly and cost-effectively at the point of care without exposure to ionizing radiation or toxic dies. The technology was developed by a talented team of cardiologists and chemical engineers at Drexel University with grant funding from the Coulter-Drexel Program and the inventors partnered with a team of successful serial healthcare entrepreneurs who have worked together for over 15 years across multiple companies to form Sonnest.